SP-146

CAS No. ——

SP-146( —— )

Catalog No. M22413 CAS No. ——

SP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 357 In Stock
10MG 597 In Stock
25MG 882 In Stock
50MG 1350 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SP-146
  • Note
    Research use only, not for human use.
  • Brief Description
    SP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).
  • Description
    SP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Aurora Kinase
  • Recptor
    Aurora B
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    453.47
  • Molecular Formula
    C25H20FN7O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:91 mg/mL (200.67 mM)
  • SMILES
    Cn1cc(cn1)c2ccc5c(c2)ncnc5Nc4cccc(NC(=O)Nc3cccc(F)c3)c4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lakkaniga R , Zhang L , Belachew B , et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression[J]. European Journal of Medicinal Chemistry, 2020, 203:112589.
molnova catalog
related products
  • XU1

    XU1(Benzo[c][1,8]naphthyridin-6(5h)-One) is an Aurora protein kinase inhibitor used for the treatment of diseases suitable for inhibition, regulation or modulation of kinase signaling.

  • AS 703569

    Cenisertib (AS 703569;R763) is a novel potent, orally available inhibitor of Aurora kinases, exhibits signifficant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo (A549 EC50=9 nM).

  • Pilaralisib

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).